S&P 500   4,076.57 (-0.09%)
DOW   34,395.01 (-0.56%)
QQQ   293.54 (+0.06%)
AAPL   148.23 (+0.14%)
MSFT   254.49 (-0.25%)
META   120.45 (+1.99%)
GOOGL   100.94 (-0.05%)
AMZN   95.35 (-1.23%)
TSLA   194.67 (-0.02%)
NVDA   171.35 (+1.25%)
NIO   12.08 (-5.48%)
BABA   85.93 (-1.86%)
AMD   77.45 (-0.23%)
T   19.16 (-0.62%)
MU   55.39 (-3.92%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.28 (-0.80%)
DIS   98.70 (+0.85%)
AMC   8.16 (+12.86%)
PYPL   78.51 (+0.13%)
PFE   51.15 (+2.03%)
NFLX   316.88 (+3.71%)
S&P 500   4,076.57 (-0.09%)
DOW   34,395.01 (-0.56%)
QQQ   293.54 (+0.06%)
AAPL   148.23 (+0.14%)
MSFT   254.49 (-0.25%)
META   120.45 (+1.99%)
GOOGL   100.94 (-0.05%)
AMZN   95.35 (-1.23%)
TSLA   194.67 (-0.02%)
NVDA   171.35 (+1.25%)
NIO   12.08 (-5.48%)
BABA   85.93 (-1.86%)
AMD   77.45 (-0.23%)
T   19.16 (-0.62%)
MU   55.39 (-3.92%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.28 (-0.80%)
DIS   98.70 (+0.85%)
AMC   8.16 (+12.86%)
PYPL   78.51 (+0.13%)
PFE   51.15 (+2.03%)
NFLX   316.88 (+3.71%)
S&P 500   4,076.57 (-0.09%)
DOW   34,395.01 (-0.56%)
QQQ   293.54 (+0.06%)
AAPL   148.23 (+0.14%)
MSFT   254.49 (-0.25%)
META   120.45 (+1.99%)
GOOGL   100.94 (-0.05%)
AMZN   95.35 (-1.23%)
TSLA   194.67 (-0.02%)
NVDA   171.35 (+1.25%)
NIO   12.08 (-5.48%)
BABA   85.93 (-1.86%)
AMD   77.45 (-0.23%)
T   19.16 (-0.62%)
MU   55.39 (-3.92%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.28 (-0.80%)
DIS   98.70 (+0.85%)
AMC   8.16 (+12.86%)
PYPL   78.51 (+0.13%)
PFE   51.15 (+2.03%)
NFLX   316.88 (+3.71%)
S&P 500   4,076.57 (-0.09%)
DOW   34,395.01 (-0.56%)
QQQ   293.54 (+0.06%)
AAPL   148.23 (+0.14%)
MSFT   254.49 (-0.25%)
META   120.45 (+1.99%)
GOOGL   100.94 (-0.05%)
AMZN   95.35 (-1.23%)
TSLA   194.67 (-0.02%)
NVDA   171.35 (+1.25%)
NIO   12.08 (-5.48%)
BABA   85.93 (-1.86%)
AMD   77.45 (-0.23%)
T   19.16 (-0.62%)
MU   55.39 (-3.92%)
CGC   3.93 (+8.56%)
F   14.08 (+1.29%)
GE   85.28 (-0.80%)
DIS   98.70 (+0.85%)
AMC   8.16 (+12.86%)
PYPL   78.51 (+0.13%)
PFE   51.15 (+2.03%)
NFLX   316.88 (+3.71%)
NASDAQ:EOLS

Evolus - EOLS Stock Forecast, Price & News

$7.31
+0.07 (+0.97%)
(As of 12/1/2022 03:59 PM ET)
Add
Compare
Today's Range
$7.11
$7.36
50-Day Range
$7.07
$8.95
52-Week Range
$5.06
$14.34
Volume
11,951 shs
Average Volume
403,543 shs
Market Capitalization
$411.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.80

Evolus MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
105.3% Upside
$14.80 Price Target
Short Interest
Healthy
6.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.96mentions of Evolus in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$969,967 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.12) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

403rd out of 1,047 stocks

Pharmaceutical Preparations Industry

170th out of 512 stocks

EOLS stock logo

About Evolus (NASDAQ:EOLS) Stock

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Stock News Headlines

Evolus Third Quarter 2022 Earnings: Revenues Disappoint
This Options Play Could Turn That Frown Upside Down - RealMoney
See More Headlines
Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Company Calendar

Last Earnings
11/08/2022
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/02/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EOLS
Fax
N/A
Employees
167
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.80
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+102.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-46,810,000.00
Pretax Margin
-56.85%

Debt

Sales & Book Value

Annual Sales
$99.67 million
Book Value
$0.52 per share

Miscellaneous

Free Float
52,141,000
Market Cap
$411.19 million
Optionable
Optionable
Beta
1.96

Key Executives

  • Mr. David MoatazediMr. David Moatazedi (Age 44)
    Pres, CEO & Director
    Comp: $1.23M
  • Dr. Rui Avelar C.CFP (Age 60)
    Dip.SportMed, M.D., Chief Medical Officer and Head of R&D
    Comp: $660.08k
  • Ms. Sandra Beaver
    Chief Financial Officer
  • Mr. David K. Erickson
    VP of Investor Relations
  • Mr. Jeffrey J. Plumer
    Gen. Counsel
  • Mr. Kurt Knab
    VP of Sales
  • Ms. Crystal Muilenburg (Age 42)
    Chief Marketing Officer
  • Ms. Jessica Novak
    Sr. VP of HR













EOLS Stock - Frequently Asked Questions

Should I buy or sell Evolus stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EOLS shares.
View EOLS analyst ratings
or view top-rated stocks.

What is Evolus' stock price forecast for 2023?

5 Wall Street research analysts have issued twelve-month target prices for Evolus' stock. Their EOLS share price forecasts range from $10.00 to $20.00. On average, they predict the company's share price to reach $14.80 in the next twelve months. This suggests a possible upside of 104.4% from the stock's current price.
View analysts price targets for EOLS
or view top-rated stocks among Wall Street analysts.

How have EOLS shares performed in 2022?

Evolus' stock was trading at $6.51 at the beginning of the year. Since then, EOLS stock has increased by 11.2% and is now trading at $7.24.
View the best growth stocks for 2022 here
.

Are investors shorting Evolus?

Evolus saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 2,340,000 shares, a decline of 8.2% from the October 31st total of 2,550,000 shares. Based on an average trading volume of 411,800 shares, the days-to-cover ratio is presently 5.7 days. Currently, 6.3% of the shares of the stock are short sold.
View Evolus' Short Interest
.

When is Evolus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our EOLS earnings forecast
.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) posted its quarterly earnings data on Tuesday, November, 8th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.05. The firm earned $33.90 million during the quarter, compared to analysts' expectations of $36.94 million. Evolus had a negative net margin of 56.88% and a negative trailing twelve-month return on equity of 141.07%.

What guidance has Evolus issued on next quarter's earnings?

Evolus issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $150.00 million-$150.00 million, compared to the consensus revenue estimate of $149.97 million.

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolus own?
When did Evolus IPO?

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Who are Evolus' major shareholders?

Evolus' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.26%), Vanguard Group Inc. (3.34%), Boothbay Fund Management LLC (1.65%), State Street Corp (1.63%), Nuveen Asset Management LLC (1.61%) and Essex Investment Management Co. LLC (0.65%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar and Vikram Malik.
View institutional ownership trends
.

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $7.24.

How much money does Evolus make?

Evolus (NASDAQ:EOLS) has a market capitalization of $407.25 million and generates $99.67 million in revenue each year. The company earns $-46,810,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis.

How many employees does Evolus have?

The company employs 167 workers across the globe.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for the company is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at ir@evolus.com.

This page (NASDAQ:EOLS) was last updated on 12/1/2022 by MarketBeat.com Staff